Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study

Junmei Wang

Journal of Chemical Information and Modeling · 2020 · 495 citations · 47 references

DOIFull text

Open access

Concepts

TL;DR

COVID‑19, caused by SARS‑CoV‑2, has prompted a search for market‑available drug treatments, and the availability of detailed viral protein structures makes computer‑aided drug design an efficient strategy. The study aims to rapidly identify promising drug repurposing candidates for COVID‑19 using computer‑aided design after viral protein structures were resolved. Using the crystal structure of SARS‑CoV‑2 main protease bound to inhibitor N3, the authors performed virtual docking of approved drugs and clinical‑trial candidates, then refined top hits with molecular dynamics and MM‑PBSA‑WSAS binding‑free‑energy calculations.

Abstract

The recent outbreak of novel coronavirus disease-19 (COVID-19) calls for and welcomes possible treatment strategies using drugs on the market. It is very efficient to apply computer-aided drug design techniques to quickly identify promising drug repurposing candidates, especially after the detailed 3D structures of key viral proteins are resolved. The virus causing COVID-19 is SARS-CoV-2. Taking advantage of a recently released crystal structure of SARS-CoV-2 main protease in complex with a covalently bonded inhibitor, N3 (Liu et al., 10.2210/pdb6LU7/pdb), I conducted virtual docking screening of approved drugs and drug candidates in clinical trials. For the top docking hits, I then performed molecular dynamics simulations followed by binding free energy calculations using an end point method called MM-PBSA-WSAS (molecular mechanics/Poisson-Boltzmann surface area/weighted solvent-accessible surface area; Wang,

References

47